Fig. 6

PX-478 increased brain infarct volume and exacerbated neurological deficit. A Photographs shows the brain infarct volume in the PBS-treated, EPC-treated, EPC and PX-478 co-treated and PX-478 alone mice at 24 h after tMCAO. B Bar graph shows the quantification of the infarct volume in the four aforementioned groups, respectively. Data are mean ± SD, n = 6–7 per group. *p < 0.05, EPC-treated vs. PBS-treated group. ^# p < 0.01, EPC- treated vs. EPC and PX-478 co-treated and PX-478 alone group. C Bar graph shows the mNSS in the EPC-treated, PBS-treated, EPC and PX-478 co-treated and PX-478 alone group at 24 h after tMCAO. Data are mean ± SD, n = 10–11 per group. ^* p < 0.05, EPC-treated vs. PBS-treated mice, EPC and PX-478 co-treated and PX-478 alone group. D Bar graphs shows HIF-1α mRNA level in the four aforementioned groups at 24 h after tMCAO. Data are mean ± SD, n = 4 per group. *p < 0.05, EPC-treated vs. PBS-treated group. ^# p < 0.01, EPC- treated vs. EPC and PX-478 co-treated and PX-478 alone group. PX = PX-478-treated mice. EPC endothelial progenitor cell, HIF-1α hypoxia-inducible factor-1α, PBS phosphate-buffered saline